Prof. Dr. Ahmet Sezer

Medical Park Seyhan-ის საავადმყოფო — სამედიცინო ონკოლოგია

ფილტვის კიბო

ძუძუს კიბო

თავისა და კისრის კიბო

რბილი ქსოვილების სიმსივნეები

იმუნოთერაპია

მიზნობრივი მედიკამენტური თერაპია

ქიმიოთერაპია

მხარდამჭერი მკურნალობა

Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604. DOI: 10.1016/S0140-6736(21)00228-2. PMID: 33581821.

Pérol M, Yoshida T, Ahn MJ, et al. Tarlatamab-Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2026 Oct 24. Online ahead of print. DOI: 10.1056/NEJMoa2609482. PMID: 42929702.

Sezer A, Sumbul AT, Abali H. Is it rational to continue anti-neoplastics with minimal toxicity even after progression in patients with no other options? Possibly yes. Asian Pac J Cancer Prev. 2014;15(2):1061–1062. DOI: 10.7314/apjcp.2014.15.2.1061. PMID: 24568451.

Gandara DR, Makharadze T, Gümüş M, et al. Association Between Patient-Reported Outcomes and Overall Survival in Patients with Advanced NSCLC Treated with First-Line Cemiplimab-Based Therapy. Cancers (Basel). 2026;18(6):916. DOI: 10.3390/cancers18060916. PMID: 41899521.

Gandara D, Gogishvili M, Sezer A, et al. Composite patient-reported outcomes and risk prediction for overall survival in advanced non-small cell lung cancer with first-line cemiplimab. Front Oncol. 2026;16:1676687. DOI: 10.3389/fonc.2026.1676687. PMID: 41821892.

Sezer A, Akkus B, Guler OC, Onal HC, Sumbul AT. Concurrent versus sandwich treatment in adjuvant treatment in high risk operated gastric cancer: A single center experience. J BUON. 2020;25(5):2341–2349. PMID: 33277854.